Product Name: EGFR Antibody [SPM622]
Species Reactivity: Human
Tested Applications: Flow, IF, IHC-P
Applications: Flow Cytometry: 0.5-1 ug/million cells in 0.1mlImmunofluorescence: 1-2 ug/mlImmunohistochemistry (FFPE): 2-4 ug/ml for 30 min at RT (1)Prediluted format : incubate for 30 min at RT (2)Optimal dilution of the anti-EGFR antibody should be determined by the researcher.1. Digest formalin-fixed tissues with Protease at 1mg/ml PBS, pH 7.4 for 10 min at 37oC2. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min.
User Note: Optimal dilutions for each application to be determined by the researcher
Predicted Molecular Weight:
Immunogen: Human EGFR purified from A431 cells was used as the immunogen for the anti-EGFR antibody.
Host Species: Mouse
Purification: Protein G affinity chromatography
Physical State: Liquid
CAS NO.: 1021950-26-4
Product: Tyrosine kinase inhibitor
Buffer: PBS with 0.1 mg/ml BSA and 0.05% sodium azide
Concentration: 0.2 mg/mL
Storage Conditions: Aliquot and Store at -20C. Avoid freez-thaw cycles.
Clonality: Monoclonal
Conjugate: Unconjugated
Alternate Names: Epidermal growth factor receptor, Proto-oncogene c-ErbB-1, Receptor tyrosine-protein kinase erbB-1, EGFR, ERBB, ERBB1, HER1
Accession NO.:
Protein Ino:
Official Symbol: EGFR
Geneid: 1956
Background: This mAb recognizes a protein of 170kDa, identified as EGFR. EGFR is type I receptor tyrosine kinase with sequence homology to erbB-1, -2, -3 -4 or HER-1, -2, -3 -4. It binds to Epidermal Growth Factor (EGF), Transforming Growth Factor-a (TGF-a), Heparin-binding EGF (HB-EGF), amphiregulin, betacellulin and epiregulin. EGFR is overexpressed in tumors of breast, brain, bladder, lung, gastric, head & neck, esophagus, cervix, vulva, ovary, and endometrium. It is predominantly present in squamous cell carcinomas.
PubMed ID:http://aac.asm.org/content/39/7/1430.abstract